- Home
- MYGN vs TROX Comparison
MYGN vs TROX Comparison
Compare MYGN & TROX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- TROX
- Stock Information
- Founded
- MYGN 1991
- TROX 2018
- Country
- MYGN United States
- TROX United States
- Employees
- MYGN N/A
- TROX N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- TROX Major Chemicals
- Sector
- MYGN Health Care
- TROX Industrials
- Exchange
- MYGN Nasdaq
- TROX Nasdaq
- Market Cap
- MYGN 642.0M
- TROX 640.4M
- IPO Year
- MYGN 1995
- TROX 2005
- Fundamental
- Price
- MYGN $8.33
- TROX $3.87
- Analyst Decision
- MYGN Hold
- TROX Hold
- Analyst Count
- MYGN 13
- TROX 8
- Target Price
- MYGN $13.50
- TROX $4.56
- AVG Volume (30 Days)
- MYGN 959.5K
- TROX 4.2M
- Earning Date
- MYGN 11-04-2025
- TROX 11-05-2025
- Dividend Yield
- MYGN N/A
- TROX 5.22%
- EPS Growth
- MYGN N/A
- TROX N/A
- EPS
- MYGN N/A
- TROX N/A
- Revenue
- MYGN $832,900,000.00
- TROX $2,949,000,000.00
- Revenue This Year
- MYGN $0.06
- TROX N/A
- Revenue Next Year
- MYGN $5.68
- TROX $3.93
- P/E Ratio
- MYGN N/A
- TROX N/A
- Revenue Growth
- MYGN 3.83
- TROX 0.24
- 52 Week Low
- MYGN $3.76
- TROX $2.95
- 52 Week High
- MYGN $22.92
- TROX $13.77
- Technical
- Relative Strength Index (RSI)
- MYGN 64.16
- TROX 49.48
- Support Level
- MYGN $7.68
- TROX $3.48
- Resistance Level
- MYGN $8.25
- TROX $3.75
- Average True Range (ATR)
- MYGN 0.38
- TROX 0.26
- MACD
- MYGN -0.01
- TROX 0.03
- Stochastic Oscillator
- MYGN 78.80
- TROX 56.70
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About TROX Tronox Holdings plc (UK)
Tronox Holdings PLC is a vertically integrated manufacturer of TiO2 pigment. It operates titanium-bearing mineral sand mines and beneficiation and smelting operations in Australia & South Africa to produce feedstock materials that can be processed into TiO2 for pigment, high-purity titanium chemicals, including titanium tetrachloride, and ultrafine TiO2 used in certain specialty applications. TiO2 and titanium feedstock, are used to produce paints and coatings, as well as plastics, paper, and printing ink. It has three pigment production facilities in the United States, the Netherlands, and Western Australia and three mining operations in Western Australia and South Africa. Europe, the Middle East, and Africa regions contribute the majority of revenue.